title: Future therapeutic directions in reverse cholesterol transport.
abstract: Despite a robust inverse association between high-density lipoprotein (HDL) cholesterol levels and atherosclerotic cardiovascular disease, the development of new therapies based on pharmacologic enhancement of HDL metabolism has proven challenging. Emerging evidence suggests that static measurement of HDL levels has inherent limitations as a surrogate for overall HDL functionality, particularly with regard to the rate of flux through the macrophage reverse cholesterol transport (RCT) pathway. Recent research has provided important insight into the molecular underpinnings of RCT, the process by which excess cellular cholesterol is effluxed from peripheral tissues and returned to the liver for ultimate intestinal excretion. This review discusses the critical importance and current strategies for quantifying RCT flux. It also highlights therapeutic strategies for augmenting macrophage RCT via three conceptual approaches: 1) improved efflux of cellular cholesterol via targeting the macrophage; 2) enhanced cholesterol efflux acceptor functionality of circulating HDL; and 3) increased hepatic uptake and biliary/intestinal excretion.
authors.affiliation: Institute for Translational Medicine and Therapeutics and Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Amit V
authors.initials: AV
authors.lastname: Khera
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Rader
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D001692:Biological Transport / Q000502:physiology*; D008076:Cholesterol, HDL / Q000378:metabolism*; D018450:Disease Progression; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D008264:Macrophages / Q000378:metabolism*; D011379:Prognosis
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL